Qfu 6.11 (qfu 6-1).1
Quentin F. Urquhart, Jr.
400 Poydras Street, Suite 2700
New Orleans, Louisiana 70130
Quentin defends individual and multi-party personal injury and property damage claims. A major focus of his
practice is in the products liability area and includes claims involving pharmaceuticals, medical devices, trucks,
recreational vehicles, hydraulic components, electrical components, and industrial machinery. In the toxic tort
area, Quentin has defended class actions and individual claims involving pesticides, termiticides, solvents,
fumigants, agricultural and household products, construction materials, radiation exposures, and asbestos.
Quentin also routinely defends claims in the areas of consumer fraud, premises liability, automotive/ trucking,
nursing home liability, and industrial accidents.
Quentin’s complex litigation and mass tort experience includes multiple roles in a wide variety of matters
including: Apple iPhone 3G Marketing MDL: Liaison Counsel; Reglan®: National Coordinating Counsel;
Norplant® Contraceptive: Louisiana Trial and Coordinating Counsel; Chinese Manufactured Drywall MDL:
Hormone Replacement Therapy: Regional Counsel; Louisiana Trial Counsel; Albuterol Sulfate: National
Liaison Counsel (vendors); Rezulin®: Louisiana and National Trial Counsel; Propulsid® MDL: National Trial
Team; Cox-II MDL Litigation: National Trial Team; Orthopedic Knee Implants: National Trial Team; HTR-
PMI Implants: Louisiana Trial Counsel; Imitrex®: Louisiana Trial Counsel and National Trial Team; Wood
Destroying Organisms: National and Regional Counsel; Penile Implants: Louisiana Trial Counsel/National Trial
Team; Breast Implants: Louisiana Trial Counsel; Insecticides: Louisiana Trial Counsel; Synthetic Stucco:
Louisiana Trial Counsel; Termiticides: Louisiana Trial Counsel.
Quentin’s Martindale-Hubbell rating is AV®.* Affiliations, Activities, and Accomplishments
Quentin served as President of the International Association of Defense Counsel (IADC) from 2012-2013. Prior
to his election as President, Quentin served on the IADC Board of Directors (2008-2012), was Major CLE
Program Chair for the 2009 IADC Mid-Year Meeting, and chaired the IADC Drug, Device & Biotechnology
Committee from 2002 to 2004. He also served as a member of the 2005 IADC Trial Academy. He is currently
a member of the Board of Directors of the Defense Research Institute (DRI) and the Lawyers for Civil Justice
(LCJ). He is also an active member of the American Bar Association (ABA), the Product Liability Advisory
Council (PLAC), the Federation of Defense and Corporate Counsel (FDCC), and the Louisiana Association of
Defense Counsel (LADC). In 2013, he was appointed by Chancellor Jack Weiss as a member of the Law Center
Alumni Board of Trustees for LSU Paul M. Hebert Law Center.
Quentin is admitted to practice before the United States Supreme Court, all Louisiana state courts, the United
States Court of Appeals for the Fifth Circuit, and the United States District Courts for the Eastern, Middle, and
Western Districts of Louisiana. He has also been admitted to practice in numerous courts across the United
States on a pro hac
*CV, BV, and AV are registered certification marks of Reed Elsevier Properties Inc., used in accordance with the Martindale-Hubbell certification
procedures, standards, and policies
Quentin received his B.S. (1981) from Trinity University, where he majored in Business Administration and
graduated cum laude
. He received his J.D. (1984) from Louisiana State University Paul M. Hebert Law Center
where he was elected President of his Senior Class. Quentin received an L.L.M., with distinction
Energy & Environmental Law from Tulane University School of Law.
Quentin has been recognized by many of the leading peer-review publications in the legal profession, including:
“The Best Lawyers in America”** in the areas of Insurance Law, Litigation – Environmental, Product Liability
Litigation- Defendants, and Mass Tort Litigation/ Class Action - Defendants by Best Lawyers, “Who’s Who of
International Product Liability Defense Lawyers” and “The International Who’s Who of Life Sciences
Lawyers” by Law Business Research, Ltd., as well as “Super Lawyers” by Thomson Reuters where he is listed
as one of the top 50 attorneys in Louisiana. In 2012 he was recognized by Who’s Who Legal to be one of the
top ten most highly regarded Product Liability Defence Lawyers in the world. In 2007 he was listed by New
as one of the Top 50 Lawyers in the New Orleans area, based on his work in the fields of
Litigation, Products Liability, and Toxic Torts.
David M. Melancon, Ali A. Spindler, & Quentin F. Urquhart, Jr., Pre-Service Removal Exception to the Forum
Defendant Rule Post Amendment of the Federal Jurisdictional Statutes
, IADC Trial Techniques and Tactics
Committee, March 2012.
Quentin F. Urquhart, Jr. & Edward W. Trapolin, Supreme Court Continues Effort To Provide Guidance For
Achieving “Error Free” Punitive Damages Awards
, IADC Drug, Device and Biotech Committee Newsletter,
Quentin F. Urquhart, Jr. authored the chapter on "Toxicology" in Challenging Expert Testimony
Lexis Publishing in 2000.
Quentin F. Urquhart, Jr., Medtronic v. Lohr: Is There A Future For Preemption In Medical Device Cases?
Defense Counsel Journal 45 (1997).
Quentin F. Urquhart, Jr., A Primer On Utilizing The Internet In Litigation Practice
, 64 Defense Counsel Journal
Quentin F. Urquhart, Jr., Joiner v. General Electric: The Next Chapter In The Supreme Court's Handling Of
, For the Defense, September 1997.
Quentin F. Urquhart, Jr., Amount In Controversy And Removal: Current Trends And Strategic Considerations
62 Defense Counsel Journal 509 (1995).
Quentin F. Urquhart, Jr., The Importance Of Documentation In Defending Termite Damage Claims
Control Magazine, June 1993.
Quentin F. Urquhart, Jr., Waiver of Defects In Removal Jurisdiction: Another Path Into Federal Court
, For The
Defense, December 1992.
Quentin F. Urquhart, Jr., The Basics of Termite Contractor Liability
, Pest Control Technology, February 1992.
** Copyright 2012 by Woodward/White, Inc., of Aiken, S.C
Attestation de conformité du site « Base de données publique des médicaments » Attestation de conformité de « Base de données publique des médicaments » Identité du déclarant ANSM143-147, boulevard Anatole France93285 Saint-Denis CedexFRANCE Date de la déclaration Cette déclaration a été établie le 25 septembre 2013 Règles, version et URI • RGAA version 2.2.1 (
Pharmacologic Treatment of Alzheimer’s Disease • Recommended use of Cholinesterase Inhibitors (ChEIs) and • Research findings for these treatments agents Other treatment agents, including supplements When to discontinue pharmacologic treatment No pharmacologic treatments currently available for Alzheimer’s disease offer a “cure” for the disease. However, early diagnosi